Market research
6RC.F ReproCELL Incorporated
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 62M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.54
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3974770004
- Market cap
- 62M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.54
About
About ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes. The company also provides Alvetex 3D, a cell culture system; Alvetex, an advanced tissue bioengineering system; EZSPHERE Multiwell Dishes and Plates; KOKEN atelocollagen; ABLE Biott bioreactor systems; and 2mag stirrer systems. In addition, It offers research stem cell, genomics, clinical stem cell research, preclinical and drug discovery, precision medicine, human tissue samples, clinical laboratory, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6RC.F discussion.
5 years, 6 months ago
ReproCELL Incorporated is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.2.
ReproCELL Incorporated's total revenue rose by 2.3% to $334M since the same quarter in the previous year.
Its net income has dropped by 28.3% to $-292M since the same quarter in the previous year.
Based on the above factors, ReproCELL Incorporated gets an overall score of 2/5.